baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

GILEAD SCIENCES INC/ US3755581036 /

- -	Chg. -	Volume	Bid-	Ask-	Market Capitalization	Dividend Y.	P/E Ratio
-USD	-	- Turnover: -	-Bid Size: -	-Ask Size: -	95.94 bill.USD	3.90%	16.96

GlobeNewswire 01/07 HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment o...

GlobeNewswire 01/07 Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Offi...

GlobeNewswire 28/06 Ensho Therapeutics Launches with Phase 2-Ready Oral α4β7 Inhibitor for Inflammatory Bowel Disease

GlobeNewswire 26/06 Neurona Therapeutics Appoints Dr. Nadia Agopyan as Senior Vice President of Regulatory Affairs

GlobeNewswire 26/06 Oruka Therapeutics Announces Key Additions to Leadership Team and Board of Directors

TeleTrader 20/06 US opens mostly higher after labor, housing data

GlobeNewswire 18/06 Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation C...

GlobeNewswire 17/06 Assembly Biosciences Announces $12.6 Million in Equity Financings

GlobeNewswire 10/06 Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus He...

GlobeNewswire 22/05 Assembly Biosciences to Present Data at Upcoming International Herpesvirus Workshop and EASL Congres...

GlobeNewswire 14/05 Xilio Therapeutics Announces Pipeline and Business Updates and First Quarter 2024 Financial Results

GlobeNewswire 09/05 MacroGenics Provides Update on Corporate Progress, First Quarter 2024 Financial Results and Interim ...

GlobeNewswire 09/05 HOOKIPA Pharma Reports First Quarter 2024 Financial Results and Recent Business Highlights

GlobeNewswire 08/05 Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update

GlobeNewswire 08/05 Assembly Biosciences Reports First Quarter 2024 Financial Results and Recent Highlights

GlobeNewswire 29/04 Atossa Therapeutics Announces Expanded Research Agreement with Weill Cornell Medicine to Further Eva...

GlobeNewswire 19/04 ACTG Announces Launch of Clinical Trial Evaluating Combination of Three Novel Immune-based Therapies...

GlobeNewswire 10/04 Nurix Therapeutics Reports First Quarter Fiscal 2024 Financial Results and Provides a Corporate Upda...

GlobeNewswire 03/04 Opthea Appoints Sujal Shah to the Board of Directors

GlobeNewswire 02/04 Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer

GlobeNewswire 02/04 Nurix Therapeutics Announces Extension of Strategic Collaboration with Gilead Sciences

GlobeNewswire 01/04 Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Fin...

GlobeNewswire 28/03 Assembly Biosciences Reports Fourth Quarter and Year End 2023 Financial Results and Recent Highlight...

GlobeNewswire 28/03 Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing

GlobeNewswire 28/03 Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program

GILEAD SCIENCES INC/ US3755581036 /

If you wish to receive reply to your feedback, please provide your email address.